Annovis Bio's Options: A Look at What the Big Money is Thinking

Financial giants have made a conspicuous bearish move on Annovis Bio. Our analysis of options history for Annovis Bio ANVS revealed 9 unusual trades.

Delving into the details, we found 11% of traders were bullish, while 88% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $207,261, and 5 were calls, valued at $158,545.

Projected Price Targets

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $15.0 and $27.5 for Annovis Bio, spanning the last three months.

Volume & Open Interest Development

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Annovis Bio's options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Annovis Bio's whale activity within a strike price range from $15.0 to $27.5 in the last 30 days.

Annovis Bio Option Activity Analysis: Last 30 Days

Largest Options Trades Observed:

About Annovis Bio

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.

Following our analysis of the options activities associated with Annovis Bio, we pivot to a closer look at the company's own performance.

Annovis Bio's Current Market Status

• Currently trading with a volume of 1,404, the ANVS's price is up by 4.71%, now at $12.0.
• RSI readings suggest the stock is currently may be approaching overbought.
• Anticipated earnings release is in 74 days.

Expert Opinions on Annovis Bio

1 market experts have recently issued ratings for this stock, with a consensus target price of $36.0.

• An analyst from Canaccord Genuity has revised its rating downward to Buy, adjusting the price target to $36.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Annovis Bio with Benzinga Pro for real-time alerts.